Mr. Joel Shacker reports

CORE ONE LABS' AKOME REVEALS IMPRESSIVE RESULTS FOR ITS PSYCHEDELIC BIO-COMPOUNDS DESIGNED TO TARGET ALZHEIMER'S AND PARKINSON'S, SHOWING POTENTIAL TO OUTPERFORM CURRENT TREATMENT METHODS

Core One Labs Inc. has shared the exciting results of its first round of Stage 2 animal model studies, carried out in collaboration with the Universitat de Barcelona on behalf of the company's wholly owned subsidiary, Akome Biotechnologies Inc. The results of the studies so far demonstrate promising outcomes, showing potential to outperform current treatment methods for Alzheimer's and Parkinson's, and marking a significant step forward in the company's pursuit of innovative treatment alternatives for common neurodegenerative diseases and mental health conditions.

These Stage 2 animal model studies mark the initial phase in the exploration of Akome's five plant bioactives, both individually and in conjunction with the psychedelic compound N, N-dimethyltryptamine (DMT), in their ability to mitigate, or eliminate, disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer disease, Parkinson's disease, ischemic stroke and depression. These studies focus on the motility of a specific C. elegans strain known as CL2006. This particular nematode strain carries a transgene responsible for progressive, adult-onset paralysis, making it a pivotal resource for Alzheimer's and Parkinson's drug discovery research.

During the initial round of Stage 2 animal model studies, five distinct dose-response assay sets were executed to investigate the effects on motility of the CL2006 strain of five biocompounds when combined with DMT. The results showed a significant improvement in the motility of the CL2006 C. elegans strain after exposure to a combination of biocompounds and DMT, surpassing the effects observed when they are administered individually. Moreover, the assays revealed a complete absence of toxicity in the model when the biocompounds and the psychedelic compound were administered together. These results represent a significant milestone and mark a vital step toward identifying the optimal combination of biocompounds and DMT for advanced animal studies using models like mice or rats.

Joel Shacker, Core One's chief executive officer, stated: "These extraordinary results underscore our unwavering commitment to advancing the fields of neuroscience and psychedelics. The potential for transformative therapies in the treatment of neurodegenerative diseases is increasing the further we move along our path of proving out the potential of our proprietary biocompounds combined with psychedelic compounds."

The compelling outcomes from these dose-response assays have ignited a profound sense of optimism within Core One's research team, prompting the decision to initiate further Stage 2 studies. These new studies will explore elevated concentration levels of biocompounds while maintaining a consistent concentration of the psychedelic compound to decrease the potential of treatment-limiting side effects. Building on the preliminary results of today's first round of Stage 2 studies, Core One's researchers hypothesize that the reduction of motor dysfunction in the model will be further enhanced with increased concentrations of the patent-pending biocompounds.

The company's investigators are also poised to conduct these dose-response assay studies with combination of Akome biocompounds and additional psychedelic compounds in the coming months, continuing their scientific journey in hopes of bringing science closer to groundbreaking therapeutic breakthroughs, inspiring hope and opening doors to new horizons in the field of neuroscience.

About Core One Labs Inc.

Core One is a life science biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the integration of novel delivery system technology.

The company has a multifaceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelic market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for the patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders under its 100-per-cent-owned subsidiary Akome, and three provisional patents under its other 100-per-cent-owned subsidiary Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics, the company intends to integrate a rollout of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

We seek Safe Harbor.